Roche Boosts AI Infrastructure with Additional Nvidia Chips, Stock Rises

FomoAnxiety · 2026-03-17T13:13:54+00:00

Roche is expanding its AI infrastructure by deploying over 2,000 Nvidia GPUs, enhancing its capacity for drug development and diagnostics. Despite this advancement, Wall Street maintains a Hold rating on Roche stock, highlighting concerns over future pipeline updates.

FomoAnxiety

2026-03-17 13:13:54

Abstract generation in progress

Swiss pharma giant Roche RHHBY +2.63% ▲ announced that it is expanding its AI (artificial intelligence) infrastructure by deploying an AI factory powered by 2,176 Nvidia NVDA +1.65% ▲ GPUs (graphics processing units). Roche’s U.S.-listed shares rose 2.6% in Monday’s regular trading session.

Claim 70% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

Roche Enhances AI Capabilities with Nvidia GPUs

Roche highlighted that with the addition of the 2,176 Nvidia chips, the company’s combined on-premises and cloud infrastructure now exceeds 3,500 Blackwell GPUs, which is the “greatest announced GPU footprint available to a pharmaceutical company.”

The company expects its enhanced AI infrastructure to accelerate the development of diagnostics solutions and therapeutics. Roche’s collaboration with Nvidia began in 2023. The company expects the latest deployment of Nvidia’s Blackwell chips to boost drug development through high-quality data and AI.

Trade NVDA with leverage

Furthermore, Nvidia’s BioNeMo platform enhances Roche’s Lab-in-the-Loop, in which biological and chemical experiments are linked to the company’s AI models, enabling scientists to test hypotheses at scale and accelerate drug discovery. Similarly, NVIDIA Omniverse libraries will optimize Roche’s manufacturing, while NVIDIA Parabricks software will enhance diagnostics. In digital health, Roche leverages NVIDIA NeMo Guardrails to deliver reliable healthcare-grade conversational AI.

Is Roche Stock a Buy, Hold, or Sell?

Despite Roche’s AI focus, Wall Street is sidelined on the stock. Recently, BNP Paribas analyst Peter Verdult downgraded Roche stock to Hold from Buy with a price target of $50. The 4-star analyst lowered his estimates for Roche following the company’s recent pipeline updates, noting that major clinical updates are not coming until 2027.

Overall, Wall Street has a Hold consensus rating on Roche stock based on three Holds and one Buy recommendation. The average RHHBY stock price target of $61 indicates 18.6% upside potential. RHHBY stock has risen 19.5% over the past year.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes